11.01.09
The results of a recent randomized, double-blind, placebo-controlled, parallel-group study showed that ResistAid, from Lonza, increased the antibody (Ab) response to the 23-valent pneu-mococcal (pneumonia) vaccine.
The 72-day trial showed ResistAid positively modulated immune function by increasing the antibody response in healthy volunteers without increasing the non-specific innate immune response. Specifically, the group that ingested ResistAid demonstrated a higher IgG Ab response to the vaccine than the placebo group in two Ab subtypes (18C and 23F) at both day 51 (p=0.006 and p=0.002, respectively) and at day 72 (p=0.008 and p=0.003). There was no effect from the vaccine or LAG on salivary IgA, white blood cell count, inflammatory cytokines or complement. For further information: www.lonza.com
The 72-day trial showed ResistAid positively modulated immune function by increasing the antibody response in healthy volunteers without increasing the non-specific innate immune response. Specifically, the group that ingested ResistAid demonstrated a higher IgG Ab response to the vaccine than the placebo group in two Ab subtypes (18C and 23F) at both day 51 (p=0.006 and p=0.002, respectively) and at day 72 (p=0.008 and p=0.003). There was no effect from the vaccine or LAG on salivary IgA, white blood cell count, inflammatory cytokines or complement. For further information: www.lonza.com